Commerce Bank Trims Stock Position in Qiagen (NYSE:QGEN)

Commerce Bank lessened its holdings in shares of Qiagen (NYSE:QGEN) by 6.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,927 shares of the company’s stock after selling 313 shares during the period. Commerce Bank’s holdings in Qiagen were worth $225,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the business. Segall Bryant & Hamill LLC raised its holdings in shares of Qiagen by 1.7% during the third quarter. Segall Bryant & Hamill LLC now owns 140,842 shares of the company’s stock worth $6,418,000 after purchasing an additional 2,310 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Qiagen during the third quarter worth $253,000. Swiss National Bank raised its holdings in shares of Qiagen by 0.7% during the third quarter. Swiss National Bank now owns 665,023 shares of the company’s stock worth $30,065,000 after purchasing an additional 4,830 shares during the last quarter. Natixis Advisors LLC raised its holdings in shares of Qiagen by 9.8% during the third quarter. Natixis Advisors LLC now owns 777,135 shares of the company’s stock worth $35,414,000 after purchasing an additional 69,448 shares during the last quarter. Finally, Impax Asset Management Group plc purchased a new position in shares of Qiagen during the third quarter worth $8,236,000. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price for the company. in a report on Thursday, October 17th. Robert W. Baird raised their price target on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Finally, Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $50.88.

Qiagen Stock Up 1.2 %

Shares of NYSE QGEN opened at $43.76 on Thursday. The company’s 50-day simple moving average is $43.32 and its 200-day simple moving average is $43.73. Qiagen has a 52-week low of $39.03 and a 52-week high of $47.44. The firm has a market cap of $9.99 billion, a price-to-earnings ratio of 112.21, a price-to-earnings-growth ratio of 3.35 and a beta of 0.41. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.